Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
J Colloid Interface Sci ; 648: 865-875, 2023 Oct 15.
Article in English | MEDLINE | ID: mdl-37327629

ABSTRACT

Molecular surface reconfiguration strategies have been instrumental to performance improvements of halide perovskite photovoltaic applications in recent years. However, research into the optical properties of the lead-free double perovskite Cs2AgInCl6 on the complex reconstructed surface is still lacking. Here, blue-light excitation in double perovskite Cs2Na0.4Ag0.6InCl6 with Bi doping has been successfully achieved by excess KBr coating and ethanol-driven structural reconstruction. Ethanol drives the formation of hydroxylated Cs2-yKyAg0.6Na0.4In0.8Bi0.2Cl6-yBry in the Cs2Ag0.6Na0.4In0.8Bi0.2Cl6@xKBr interface layer. The hydroxyl group adsorbed on the interstitial sites of the double perovskite structure induces a transfer of local space electrons to the [AgCl6] and [InCl6] octahedral regions, enabling them to be excited with blue light (467 nm). The passivation of KBr shell reduces the non-radiative transition probability of excitons. Blue-light-excited flexible photoluminescence devices based on hydroxylated Cs2Ag0.6Na0.4In0.8Bi0.2Cl6@16KBr are fabricated. The application of hydroxylated Cs2Ag0.6Na0.4In0.8Bi0.2Cl6@16KBr as down-shift layer in GaAs photovoltaic cell module can increase its power conversion efficiency by 3.34%. The surface reconstruction strategy provides a new way to optimize the performance of lead-free double perovskite.

2.
Neural Regen Res ; 14(8): 1438-1444, 2019 Aug.
Article in English | MEDLINE | ID: mdl-30964070

ABSTRACT

Genome-wide studies have reported that Parkinson's disease is associated with abnormal expression of various growth factors. In this study, male C57BL/6 mice aged 10 weeks were used to establish Parkinson's disease models using an intraperitoneal injection of 60 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. 28 days later, 10 or 100 ng fibroblast growth factor 20 was injected intracerebroventricularly. The electrophysiological changes in the mouse hippocampus were recorded using a full-cell patch clamp. Expression of Kv4.2 in the substantia nigra was analyzed using a western blot assay. Serum malondialdehyde levels were analyzed by enzyme-linked immunosorbent assay. The motor coordination of mice was evaluated using the rotarod test. The results showed that fibroblast growth factor 20 decreased A-type potassium current in neurons of the substantia nigra, increased long-term potentiation amplitude in the hippocampus, and downregulated Kv4.2 expression. A high dose of fibroblast growth factor 20 reduced serum malondialdehyde levels and enhanced the motor coordination of mice. These findings confirm that fibroblast growth factor 20 has a therapeutic effect on the toxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, and its mechanism of action is associated with the inhibition of A-type K+ currents and Kv4.2 expression. All animal procedures were approved by the Animal Care and Use Committee of Qilu Hospital of Shandong University, China in 2017 (approval No. KYLL-2017-0012).

3.
Arch Insect Biochem Physiol ; 98(3): e21467, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29677385

ABSTRACT

Lectins and antimicrobial peptides (AMPs) are widely distributed in various insects and play crucial roles in primary host defense against pathogenic microorganisms. Two AMPs (cecropin and attacin) have been identified and characterized in the larvae of housefly. In this study, two novel C-type lectins (CTLs) were obtained from Musca domestica, while their agglutinating and antiviral properties were evaluated. Real-time PCR analysis showed that the mRNA levels of four immune genes (MdCTL1, MdCTL2, Cecropin, and Attacin) from M. domestica were significantly upregulated after injection with killed Gram-negative Escherichia coli. Moreover, purified MdCTL1-2 proteins can agglutinate E. coli and Staphylococcus aureus in the presence of calcium ions, suggesting their immune function is Ca2+ dependent. Sequence analysis indicated that typical WND and QPD motifs were found in the Ca2+ -binding site 2 of carbohydrate recognition domain from MdCTL1-2, which was consistent with their agglutinating activities. Subsequently, antiviral experiments indicated that MdCTL1-2 proteins could significantly reduce the infection rate of Spodoptera frugiperda 9 cells by the baculovirus Autographa californica multicapsid nucleopolyhedrovirus, indicating they might play important roles in insect innate immunity against microbial pathogens. In addition, MdCTL1-2 proteins could effectively inhibit the replication of influenza H1 N1 virus, which was similar to the effect of ribavirin. These results suggested that two novel CTLs could be considered a promising drug candidate for the treatment of influenza. Moreover, it is believed that the discovery of the CTLs with antiviral effects in M. domestica will improve our understanding of the molecular mechanism of insect immune response against viruses.


Subject(s)
Cecropins/metabolism , Houseflies/metabolism , Insect Proteins/metabolism , Lectins, C-Type/metabolism , Animals , Baculoviridae , Houseflies/genetics , Influenza A Virus, H1N1 Subtype , Lectins, C-Type/genetics , Lectins, C-Type/isolation & purification , Microbial Sensitivity Tests , Phylogeny , Sequence Analysis, DNA
4.
Zhonghua Fu Chan Ke Za Zhi ; 45(10): 754-6, 2010 Oct.
Article in Chinese | MEDLINE | ID: mdl-21176556

ABSTRACT

OBJECTIVE: to evaluate clinical efficacy and safety of levornidazole in the treatment of pelvic anaerobic infections. METHODS: a multicenter randomized controlled clinical study was conducted to evaluate clinical efficacy and safety of levornidazole. One hundred and fourty-three patients with pelvic anaerobic bacteria infection were classified into 70 cases treated by levornidazole in study group and 73 cases treated by Ornidazole in control group. Those patients in two groups were both administered at a dose of 0.5 g twice daily for 5 - 7 days. The rate of clinical efficacy, bacteria clearance and adverse effect were recorded and compared between two groups. RESULTS: at the endpoint, the rate of clinical efficacy were 80% (56/70) in study group and 81% (59/73) in control group, which did not reach significant difference (P > 0.05). The rate of bacteria clearance were 97% (36/37) in study group and 92% (22/24) in control group, which also did not reach significant difference (P > 0.05). The rate of adverse reaction of 3% (20/70) in study group was significantly lower than 22% (16/73) in control group (P < 0.05). CONCLUSION: it is effective and safe to treat pelvic anaerobic infections with levornidazole and sodium chloride injection.


Subject(s)
Anti-Infective Agents/therapeutic use , Bacteria, Anaerobic/drug effects , Bacterial Infections/drug therapy , Ornidazole/therapeutic use , Pelvic Infection/drug therapy , Adolescent , Adult , Anti-Infective Agents/administration & dosage , Anti-Infective Agents/adverse effects , Bacterial Infections/microbiology , Double-Blind Method , Female , Humans , Injections, Intravenous , Middle Aged , Ornidazole/administration & dosage , Ornidazole/adverse effects , Pelvic Infection/microbiology , Sodium Chloride/administration & dosage , Sodium Chloride/adverse effects , Sodium Chloride/therapeutic use , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...